NPPA Grants 50% Ceiling Price Hike for Anti-Tetanus Immunoglobulin Injections
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling prices of Anti-Tetanus Immunoglobulin 250 IU and 500 IU injections under the Drugs (Prices Control) Order, 2013.
The authority has exercised its extraordinary powers in public interest under Paragraph 19 of the DPCO, 2013, following review directions of the Department of Pharmaceuticals and recommendations of the concerned committee, to allow a one-time revision of ceiling prices of the said formulations.
The revision has been granted in view of rising manufacturing costs, an increase in API prices, exchange rate fluctuations, and concerns regarding financial viability and continued availability of the formulation, which is manufactured by a single company in India.
The list of revised ceiling prices includes Anti-Tetanus Immunoglobulin 250 IU Injection and Anti-Tetanus Immunoglobulin 500 IU Injection, with existing and revised ceiling prices as notified in the Gazette.
NPPA had notified the ceiling prices of Anti-Tetanus Immunoglobulin 250 IU Injection and Anti-Tetanus Immunoglobulin 500 IU Injection vide notification S.O. 5497(E) dated 19th December, 2024 under the provisions of the Drugs (Prices Control) Order, 2013 based on the Pharmarack data after applying monopoly reduction of 7.67% under Para 6 of DPCO, 2013.
Bharat Serums & Vaccines Limited filed a Review Application under paragraph 31 of the Drugs (Prices Control) Order, 2013 against the notification S.O. No. 5497(E) dated 19.12.2024, inter alia, contending that it is the sole manufacturer of Anti-Tetanus Immunoglobulin in India and, ensured continued production in public interest; however, the formulation has become financially unviable due to a significant increase in import-dependent API costs, fluctuations in exchange rates, and rising manufacturing and postmanufacturing expenses, resulting in persistent negative margins. The applicant further submitted that it had already sought upward price revision under paragraph 19 of the DPCO, 2013.
The Department of Pharmaceuticals, Government of India, after examination of the matter, issued Review Order No. 31015/03/2025-Pricing (E-30195) dated 07.04.2026 referring back the matter to NPPA for reconsideration in accordance with the precedent of Anti-Tetanus Immunoglobulin and BCG Vaccine under NLEM, 2015.
The Committee on Affordable Medicines and Health Products (CAMHP, earlier known as SCAMHP), NITI Aayog, Government of India, provided guidance on the modalities/ methodology to be followed. CAMHP in its 2nd meeting held on 07.11.2019, recommended an increase of 50% in the ceiling prices and also authorized NPPA to examine additional formulations / molecules experiencing similar issues of manufacturing unviability due to low prices and apply upward price revision on principles determined by CAMHP.
The Authority, based on the said guidance, has previously allowed one-time upward revision of ceiling prices for certain essential scheduled formulations in public interest to ensure their continued availability in the market
The committee constituted by the authority for the examination of cases under paragraph 19 of the Drugs (Prices Control) Order, 2013, in its 8th meeting held on 18.05.2026 noted that the request for anti-tetanus immunoglobulin 250 IU and 500 IU is based on an increase in raw material, excipients, and overall manufacturing costs.
The Committee noted that the formulation is manufactured by a single company, has been under price regulation since NLEM 2011, and shows a substantial increase in API price over recent years. The committee deliberated on the matter and recommended consideration of appropriate upward price revision under Paragraph 19.
The Authority, after deliberating upon the recommendations of the Committee constituted under paragraph 19 of the Drugs (Prices Control) Order, 2013, increase in API and other input costs; and the need to ensure continued availability of these critical medicines, invoked the extraordinary powers in public interest under paragraph 19 of the said Order for upward revision of the ceiling prices of the said formulations by allowing a one-time increase of 50% over the prevailing ceiling prices.
The Authority further noted that the said increase is being granted as a comprehensive measure already taking into account all relevant factors, including market structure and supply conditions, and therefore, reconsideration of monopoly reduction or any adjustment on that account is not warranted separately in the present case.
In line with the above, the notification stated,
"In exercise of extraordinary powers in public interest, conferred by paragraph 19 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the Table below as ceiling prices exclusive of Goods and Services Tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
Sl. No. | Name of Scheduled Formulation | Unit | Dosage form & Strength | Existing S.O. No. & Date | Approved revised Ceiling Price (Rs.) | |
(1) | (2) | (3) | (4) | (5) | 6(a) | 6(b) |
1 | Anti-Tetanus Immunoglobulin | As licensed (250 IU) | Per Vial | 1912.02 | 1575(E) Sl. No. 59 | 25.03.2026 |
2 | Anti-Tetanus Immunoglobulin | As licensed (500 IU) | Per Vial | 2881.19 | 1575(E) Sl. No. 60 | 25.03.2026 |
The notification further added:
To view the official order, click the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.